Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Praxis Precision Medicines Inc (PRAX)

$248.28 +7.62 (3.17%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	6.98B
Revenue (ttm)	0.00
Net Income (ttm)	-303.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	269,528
Avg Vol	438,088
Day's Range	N/A - N/A
Shares Out	27.88M
Stochastic %K	2%
Beta	2.71
Analysts	Strong Sell
Price Target	$621.76

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molec...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 300 8460

Website: praxismedicines.com

Address:

99 High Street, 30th Floor, Boston, United States

julemarinade Jun. 11 at 9:05 AM

$PRAX up 23% on no news? 🤔

1 · Reply

Hognose Jun. 10 at 1:51 PM

$ASND $PRAX too $RYTM $XBI

0 · Reply

R84877P Jun. 8 at 10:00 PM

$PRAX I love how she went to $340 after hours for 10 minutes 🫢

0 · Reply

brunoq14 Jun. 8 at 4:39 PM

$PRAX According to AI, the essential tremor market opportunity is growing and in ten years could be over $5 billion. That's the January PDUFA date. Now it's 1-2.

0 · Reply

Trainguy1 Jun. 6 at 12:34 PM

$PRAX If you read this PRAX PR from January, you will see the following blurb about PRAX R&D day. R&D day is coming this month. Lifecycle focused indication expansion across the portfolio will be presented at a Praxis R&D day in the second quarter of 2026. https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-enters-its-next-chapter-following/

0 · Reply

Bazzzigar Jun. 5 at 7:21 PM

$PRAX few more

0 · Reply

CharlieeMungerTWITS Jun. 4 at 4:32 PM

$PRAX stay right here damn it. I just need powder

1 · Reply

3_19 Jun. 4 at 3:16 PM

$PRAX every uptick is shorted

0 · Reply

3_19 Jun. 4 at 1:57 PM

$PRAX selling continues

1 · Reply

Hognose Jun. 4 at 5:07 AM

$ABVX $NUVL $PRAX all having bad news on the same day? Or just over reacting to any data right now?

0 · Reply

Praxis Precision Medicines Transcript: AGM 2026

Jun 8, 2026, 8:00 AM EDT - 3 days ago

Praxis Precision Medicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 4:01 PM EDT - 6 days ago

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 4:01 PM EDT - 8 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-02T16:19:35.000Z - 9 days ago

Praxis Precision falls -15.4%

2026-06-02T13:37:44.000Z - 9 days ago

Praxis Precision price target lowered to $616 from $715 at Truist

2026-06-02T12:23:18.000Z - 9 days ago

Praxis Precision price target lowered to $650 from $750 at Oppenheimer

2026-06-02T12:07:49.000Z - 9 days ago

Praxis Precision price target lowered to $162 from $166 at Wedbush

2026-06-02T11:42:18.000Z - 9 days ago

Praxis Precision price target lowered to $810 from $843 at BTIG

2026-06-02T11:24:46.000Z - 9 days ago

Praxis Precision price target lowered to $400 from $433 at Baird

2026-06-02T10:27:13.000Z - 9 days ago

Praxis Precision price target lowered to $1,201 from $1,245 at H.C. Wainwright

2026-06-02T08:30:10.000Z - 9 days ago

Praxis Precision price target lowered to $374 from $420 at Deutsche Bank

Jun 1, 2026, 6:11 PM EDT - 9 days ago

Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study

2026-06-01T21:09:16.000Z - 9 days ago

Praxis Precision Medicines trading resumes

2026-06-01T21:04:54.000Z - 9 days ago

Praxis Precision down 15% below $286 following POWER1 study update

2026-06-01T20:27:00.000Z - 9 days ago

Praxis Precision reports POWER1 study misses endpoint, pauses POWER2 enrollment

Jun 1, 2026, 4:15 PM EDT - 9 days ago

Praxis Precision Medicines Provides Vormatrigine Program Update

2026-06-01T20:10:09.000Z - 9 days ago

Praxis Precision Medicines trading halted, news pending

2026-05-13T13:49:43.000Z - 4 weeks ago

Praxis Precision assumed with a Buy at Truist

May 12, 2026, 7:20 PM EDT - 4 weeks ago

Praxis Precision Medicines Transcript: Bank of America Global Healthcare Conference 2026

2026-05-08T16:03:31.000Z - 4 weeks ago

Praxis Precision price target lowered to $420 from $444 at Deutsche Bank

2026-05-08T13:50:27.000Z - 4 weeks ago

Praxis Precision price target raised to $166 from $130 at Wedbush

May 7, 2026, 8:30 AM EDT - 5 weeks ago

Praxis Precision Medicines Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 5 weeks ago

Praxis Precision Medicines Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 5 weeks ago

Praxis Precision Medicines Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 5 weeks ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 5 weeks ago

Praxis Precision Medicines Slides: Corporate presentation

May 4, 2026, 4:01 PM EDT - 5 weeks ago

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Apr 30, 2026, 8:00 AM EDT - 6 weeks ago

Praxis Precision Medicines Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 6 weeks ago

Praxis Precision Medicines Proxy statement: Proxy filing

2026-04-15T12:48:12.000Z - 2 months ago

Praxis Precision price target raised to $437 from $412 at Deutsche Bank

Apr 14, 2026, 7:30 AM EDT - 2 months ago

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Mar 30, 2026, 4:01 PM EDT - 2 months ago

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Mar 2, 2026, 11:50 AM EST - 3 months ago

Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Feb 19, 2026, 8:00 AM EST - 4 months ago

Praxis Precision Medicines Earnings Call Transcript: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Praxis Precision Medicines Earnings release: Q4 2025

Feb 19, 2026, 8:00 AM EST - 4 months ago

Praxis Precision Medicines Annual report: Q4 2025

Feb 19, 2026, 7:30 AM EST - 4 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 19, 2026, 7:00 AM EST - 4 months ago

Praxis Precision Medicines Slides: Corporate presentation

Feb 11, 2026, 1:00 PM EST - 4 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 4:01 PM EST - 4 months ago

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Feb 2, 2026, 9:57 AM EST - 4 months ago

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Jan 22, 2026, 10:26 AM EST - 5 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 12, 2026, 7:00 AM EST - 5 months ago

Praxis Precision Medicines Slides: Corporate presentation

Jan 8, 2026, 4:45 PM EST - 5 months ago

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Jan 6, 2026, 11:15 PM EST - 5 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Jan 6, 2026, 4:03 PM EST - 5 months ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Dec 29, 2025, 8:00 AM EST - 5 months ago

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Dec 11, 2025, 8:00 AM EST - 6 months ago

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Dec 9, 2025, 4:01 PM EST - 6 months ago

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Dec 4, 2025, 4:10 PM EST - 6 months ago

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Dec 4, 2025, 4:01 PM EST - 6 months ago

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Nov 24, 2025, 1:00 PM EST - 7 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 20, 2025, 4:01 PM EST - 7 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Nov 18, 2025, 8:30 AM EST - 7 months ago

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 9:30 AM EST - 7 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 7:00 AM EST - 7 months ago

Praxis Precision Medicines Slides: Corporate Presentation

Nov 7, 2025, 12:30 PM EST - 7 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 5, 2025, 8:00 AM EST - 7 months ago

Praxis Precision Medicines Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 7 months ago

Praxis Precision Medicines Quarterly report: Q3 2025

Nov 3, 2025, 9:58 AM EST - 7 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 16, 2025, 11:45 PM EDT - 8 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Oct 16, 2025, 2:14 PM EDT - 8 months ago

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Oct 16, 2025, 12:02 PM EDT - 8 months ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 8:00 AM EDT - 8 months ago

Praxis Precision Medicines Transcript: Study Result

Oct 16, 2025, 8:00 AM EDT - 8 months ago

Praxis Precision Medicines Press release: Study Result

Oct 16, 2025, 8:00 AM EDT - 8 months ago

Praxis Precision Medicines Slides: Study Result

Oct 16, 2025, 7:09 AM EDT - 8 months ago

Praxis Precision Medicines' movement disorder drug shows promise in trials

Sep 29, 2025, 7:00 AM EDT - 9 months ago

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Sep 10, 2025, 8:30 AM EDT - 9 months ago

Praxis Precision Medicines Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:01 PM EDT - 9 months ago

Praxis Precision Medicines to Participate in September Investor Conferences

Sep 2, 2025, 10:00 AM EDT - 10 months ago

Praxis Precision Medicines Transcript: Post-IEC Discussion with Praxis Precision Medicines (PRAX) Webinar

Aug 25, 2025, 4:01 PM EDT - 10 months ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Aug 7, 2025, 11:00 AM EDT - 11 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Aug 5, 2025, 5:50 PM EDT - 11 months ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 5, 2025, 10:00 AM EDT - 11 months ago